...
首页> 外文期刊>Cytotherapy >Peripheral endothelial progenitor cells (CD133(+)) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up
【24h】

Peripheral endothelial progenitor cells (CD133(+)) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up

机译:外周血管内皮祖细胞(CD133(+))用于治疗肢体严重缺血患者的血管生成。一年的随访

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We present a patient with critical limb ischemia who was successfully treated with the injection of autologous peripheral blood (PB) CD133+ purified stem celly (SC) into the gastrocnemius muscle. No serious adverse events related to G-CST administration, mononuclear cells harvest or CD133+ SC administration was observed. After 17 months of follow-up, our patient hay experienced limb salvage, symptomatic relief and Junctional improvement. Moreover, we have observed the appearance of flow in the right posterior tibial artery that was absent before the procedure. To our knowledge, this is the first case of critical limb ischemia treated with PB CD133+ SC.
机译:我们介绍了患有严重肢体缺血的患者,该患者已通过向腓肠肌注射自体外周血(PB)CD133 +纯化的干细胞(SC)成功治疗。没有观察到与G-CST给药,单核细胞收获或CD133 + SC给药相关的严重不良事件。经过17个月的随访,我们的病人干草经历了肢体抢救,症状缓解和结节改善。此外,我们观察到在手术前右胫后动脉没有血流。据我们所知,这是用PB CD133 + SC治疗的第一例严重肢体缺血病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号